viewTiziana Life Sciences PLC

Tiziana Life Sciences to use four CROs to expedite development of COVID-19 treatment

The company said it intends to initiate the clinical study in the first quarter of 2021

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (Nasdaq:TLSA LON:TILS) said it has signed agreements with four contract research organisations (CROs) to expedite clinical development of COVID-19 treatment TZLS-501.

The company said it intends to initiate the clinical study in the first quarter of 2021.

FHI Clinical will run a trial of TZLS-501 delivered as an aerosol directly to the lungs using a hand-held nebulizer, said Tiziana.

STC Biologics is a boutique Good Manufacturing Practice (GMP) CRO that provides full chemistry, manufacturing and control (CMC) services.

Sciarra Labs will develop and test a hand-held nebulizer and be GMP manufacturing the anti-IL6R mAb solution to be used as clinical trial material for the study in COVID-19 patients.

ITR Laboratories Canada will conduct safety and toxicity studies with TZLS-501 delivered by a nebulizer directly into the lungs of cynomolgus monkeys.

TZLS-501 is a novel fully human mAb that binds to both the membrane-bound and soluble forms of IL-6R and rapidly depletes circulating levels of IL-6 in the blood.  Excessive production of IL-6 is regarded as a key driver of cytokine release syndrome (CRS) and chronic inflammation in the lungs of patients with COVID-19 and acute respiratory illness such as Acute Respiratory Distress Syndrome (ARDS).

In a statement, Gabriele Cerrone, executive chairman of Tiziana, said: "We have moved quickly to accelerate our clinical development plan for TZLS-501 using our innovative delivery platform, which was developed by Howard Weiner, a world-renowned neurologist and Chairman of our Scientific Advisory Board."

Tiziana holds a worldwide exclusive license for TZLS-501 from Bristol Myers Squibb.

Dr Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences, added: "Our proprietary inhalation technology for delivery of TZLS-501 to the lungs in COVID-19 patients is an attractive and most logical approach to deplete excessive levels of IL-6 to provide rapid relief. We are focusing on the development of oral, nasal and inhalation routes of mAb administration for immunotherapy."

"The common underlying concept in these alternative delivery approaches is to enable local or topical actions to maximize clinical action and minimize undesirable side effects commonly associated with intravenous and subcutaneous administration. Being a fully human anti-IL-6 receptor mAb, TZLS-501 is most suitable for long-term immunotherapies," he added.

Quick facts: Tiziana Life Sciences PLC

Price: 141 GBX

Market: AIM
Market Cap: £269.54 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...


Tiziana Life Sciences to fast-track its human coronavirus trials for...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone speaks to Proactive London's Andrew Scott after announcing they're soon to kick off a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. He says it's due to start in the next...

3 days, 20 hours ago

2 min read